Still, because the same combinatorial approach did not lead to similar outcomes in the poorly immunogenic mouse KPC1 pancreatic cancer model, these researches also suggested that combining anti-TGF-β therapies with immune checkpoint inhibitors may be beneficial only for certain types of cancer, highlighting the relevance of an appropriate selection of patients to undergo this therapeutic strategy. The gene discussed is TGFB1; the disease is familial pancreatic carcinoma.